Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.72 |
| ▸ | RAB9A | P51151 | 5/20 | 0.72 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | COMT | P21964 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.55 |
| ▸ | CLK2 | P49760 | 1/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.55 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.55 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6125947 | 0.86 | ATM (0.58) | NPC1RAB9AATMCOMT | |
| SCHEMBL15764664 | 0.85 | NPC1 (1.00) | NPC1RAB9AMAOBMEN1KMT2A | |
| SCHEMBL6125695 | 0.82 | ATM (0.79) | NPC1RAB9AHPSEATMCOMT | |
| SCHEMBL8769684 | 0.82 | COMT (0.70) | NPC1RAB9AHPSEMEN1KMT2A | |
| SCHEMBL8770068 | 0.82 | MMP2 (0.58) | HPSEATMCOMT | |
| SCHEMBL8769987 | 0.81 | ATM (0.55) | HPSEATMCOMT | |
| SCHEMBL1666758 | 0.81 | ATM (0.65) | ATMCOMT | |
| SCHEMBL14381770 | 0.79 | COMT (0.66) | NPC1RAB9AHPSECOMT | |
| SCHEMBL5415418 | 0.78 | NPC1 (0.86) | NPC1RAB9AMAOBMEN1KMT2A | |
| SCHEMBL31612364 | 0.78 | ATM (0.66) | NPC1RAB9AHPSEATMCOMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9622991-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9622991-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9144557-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9144557-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-09-10 | — | — | US | disclosed |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-09-10 | — | — | US | disclosed |
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | HGF, EPOR, MPL | NPC1 4635/4885RAB9A 4230/4885HPSE 354/4885 |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | NPC1 4555/4885RAB9A 3140/4885HPSE 635/4885 |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | NPC1 4555/4885RAB9A 3140/4885HPSE 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.